Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets
Biomolecules · 2024
DOI: 10.3390/biom14091190 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2024. Verfasst von Elena Conte und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy. Hauptthemen laut MEDLINE: Tuberous Sclerosis, Tuberous Sclerosis Complex 1 Protein. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PRIN—MIUR, Research for Innovation (REFIN) POR PUGLIA FESR-FSE 2014—2020, #NEXTGENERATIONEU.
Abstract (Originalsprache)
Tuberous sclerosis complex (TSC) is a rare multisystem disorder caused by heterozygous loss-of-function pathogenic variants in the tumour suppressor genes TSC1 and TSC2 encoding the tuberin and hamartin proteins, respectively. Both TSC1 and TSC2 inhibit the mammalian target of rapamycin (mTOR) complexes pathway, which is crucial for cell proliferation, growth, and differentiation, and is stimulated by various energy sources and hormonal signaling pathways. Pathogenic variants in TSC1 and TSC2 lead to mTORC1 hyperactivation, producing benign tumours in multiple organs, including the brain and kidneys, and drug-resistant epilepsy, a typical sign of TSC. Brain tumours, sudden unexpected death from epilepsy, and respiratory conditions are the three leading causes of morbidity and mortality. Even though several therapeutic options are available for the treatment of TSC, there is further need for a better understanding of the pathophysiological basis of the neurologic and other manifestations seen in TSC, and for novel therapeutic approaches. This review provides an overview of the main current therapies for TSC and discusses recent studies highlighting the repurposing of approved drugs and the emerging role of novel targets for future drug design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.
- Institute of Biophysics, National Research Council, 16149 Genova, Italy.
ORCID-Profile: Elena Conte, Brigida Boccanegra, Michael Pusch, Annamaria De Luca, Paola Imbrici
Förderung
- PRIN—MIUR
- Research for Innovation (REFIN) POR PUGLIA FESR-FSE 2014—2020
- #NEXTGENERATIONEU
- Italian Ministry of University and Research
- National Recovery and Resilience Plan
- MNESYS
Zitieren
APA
Conte, E., Boccanegra, B., Dinoi, G., Pusch, M., De Luca, A., Liantonio, A., & Imbrici, P. (2024). Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets. Biomolecules. https://doi.org/10.3390/biom14091190
Vancouver
Conte E, Boccanegra B, Dinoi G, Pusch M, De Luca A, Liantonio A, et al. Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets. Biomolecules. 2024. doi:10.3390/biom14091190
BibTeX
@article{Conte2024,
author = {Conte, Elena and Boccanegra, Brigida and Dinoi, Giorgia and Pusch, Michael and De Luca, Annamaria and Liantonio, Antonella and Imbrici, Paola},
title = {Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14091190}
}
EUVIMED